For the Inventor, By the Inventor

Enter assignee name

Auckland, New Zealand

Neuren Pharmaceuticals Limited

USPTO Granted Patents = 28

EPO Patents = 4

Forward Citations = 1,576

Loading Chart...

Loading Chart...

46 inventors (with patents filed for the assignee):

Margaret Anne Brimble (9 out of 21 patents)

Michael John Bickerdike (7 out of 7 patents)

Jian Guan (7 out of 12 patents)

4. Peter David Gluckman (6 out of 29 patents)

5. Frank Sieg (6 out of 9 patents)

6. Lawrence Irwin Glass (5 out of 6 patents)

7. Michael Frederick Snape (5 out of 5 patents)

8. Clive Blower (3 out of 3 patents)

9. James Anthony Bonnar (3 out of 3 patents)

10. James Murray Shaw (3 out of 3 patents)

11. Etienne David Frank Philippe Moniotte (3 out of 3 patents)

12. Martin Bernard Catherine Bousmanne (3 out of 5 patents)

13. Cecilia Betti (3 out of 5 patents)

14. Karel Willy Luc Decroos (3 out of 3 patents)

15. Mimoun Ayoub (3 out of 3 patents)

28 patents: Sort by Forward Citations

1. 12472177 - Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome (2025-11-18),

2. 12297172 - Compositions of trofinetide (2025-05-13),

3. 11866406 - Compositions of trofinetide (2024-01-09),

4. 11370755 - Compositions of trofinetide (2022-06-28),

5. 11197856 - Bicyclic compounds and methods for their use in treating autism (2021-12-14),

6. 10548892 - Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders (2020-02-04),

7. 9867823 - Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders (2018-01-16),

8. 9708366 - Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate (2017-07-18),

9. 9212204 - Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid (2015-12-15),

10. 9119851 - Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals (2015-09-01),

11. 8791117 - Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals (2014-07-29),

12. 8637567 - Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid (2014-01-28),

13. 8138304 - Neural regeneration peptides and formulations thereof (2012-03-20),

14. 8067425 - Neuroprotective bicyclic compounds and methods for their use (2011-11-29),

15. 7887839 - Oral formulations of glycyl-2-methylprolyl-glutamate (2011-02-15),

Neuren Pharmaceuticals Limited is a biopharmaceutical company engaged in the development of novel therapies for multiple or orphan neurological disorders. The company focuses on diseases with high unmet medical needs, including Rett syndrome, Fragile X syndrome, and Parkinson's disease. Neuren's innovative drug candidates aim to improve cognition, behavior, and function in patients with these conditions. With its commitment to scientific excellence and collaboration, Neuren Pharmaceuticals strives to make a significant impact on the lives of patients and their families.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

28 Patents

#12 in Auckland

#23 in New Zealand

#22,565 in the World

Auckland, New Zealand

Neuren Pharmaceuticals Limited

Forward Citations = 1,576

46 inventors:

Margaret Anne Brimble (9 out of 21 patents)

Michael John Bickerdike (7 out of 7 patents)

Jian Guan (7 out of 12 patents)

4. Peter David Gluckman (6 out of 29 patents)

5. Frank Sieg (6 out of 9 patents)

Please report any incorrect information to support@idiyas.com

Loading…